Bluejay Therapeutics Unveils Promising NASH Drug Data
Bluejay Therapeutics has revealed preclinical data on BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor designed to treat metabolic...
eClinical Tech News
Clinuvel Recruits 200 Patients in Phase III Vitiligo Trial
Clinuvel Pharmaceuticals completed enrollment of over 200 patients in its Phase III trial (CUV105) for SCENESSE® (afamelanotide 16mg) as...
Actuate Therapeutics Announces Topline Results From Phase 2 Elraglusib Trial
Actuate Therapeutics announced positive topline results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line...
Galimedix Phase 1 Dose Study of Oral Gal-101 Complete
Galimedix Therapeutics has completed the single ascending dose (SAD) portion of its Phase 1 study for oral GAL-101, a...
Barzolvolimab Shows Promise in Eosinophilic Esophagitis Phase 2 Study
Celldex presented histology data from its Phase 2 trial of barzolvolimab for eosinophilic esophagitis (EoE) at the 2025 Digestive...
Capricor Gets FDA Nod for DMD Cardiomyopathy Drug Trial
Capricor Therapeutics announced the completion of a mid-cycle review meeting with the FDA for its Biologics License Application (BLA)...
WTX-921 Shows Promising Preclinical Data for IBD Treatment
Werewolf Therapeutics presented data at IMMUNOLOGY2025 demonstrating the efficacy of WTX-921, a conditionally activated IL-10 drug, in a mouse...
OPGX-LCA5 Gene Therapy Restores Meaningful Vision in Phase 1/2 Trial
Opus Genetics announced one-year results from a Phase 1/2 study of its lead gene therapy candidate, OPGx-LCA5, for patients...
UBX1325 DME Phase 2b Study: 36-Week Results & Corporate Updates
UNITY Biotechnology announced 36-week results from its Phase 2b ASPIRE trial of UBX1325 for diabetic macular edema (DME). The...
Chemomab Announces Positive Phase 2 Nebakitug Clinical Data in PSC at DDW 2025
Chemomab Therapeutics announced positive Phase 2 SPRING trial data for nebokitug (CM-101) in primary sclerosing cholangitis (PSC) at Digestive...